Sun Pharma Announces Positive Results of Two Pivotal Phase
... treatment of moderate-to-severe plaque psoriasis, further validating the importance of the role of IL-23 in psoriasis. We are encouraged by these results and the potential to provide a new treatment option to patients with moderate-to-severe plaque psoriasis, a disease that often takes both a physic ...
... treatment of moderate-to-severe plaque psoriasis, further validating the importance of the role of IL-23 in psoriasis. We are encouraged by these results and the potential to provide a new treatment option to patients with moderate-to-severe plaque psoriasis, a disease that often takes both a physic ...
SAMi_IS_2013 - updated
... $8.9B Problem in Asthma SALBUTAMOL (a.k.a. Albuterol) is the ONLY short-acting bronchodilator – several “me toos” - all act via same B-adrenergic pathway $1.6B sales, 4th most prescribed, 15th highest selling GENERIC worldwide ...
... $8.9B Problem in Asthma SALBUTAMOL (a.k.a. Albuterol) is the ONLY short-acting bronchodilator – several “me toos” - all act via same B-adrenergic pathway $1.6B sales, 4th most prescribed, 15th highest selling GENERIC worldwide ...
THE CHIRAL SWITCH: THE DEVELOPMENT OF SINGLE
... statement for the development of new stereoisomeric drugs [24], which was closely followed by European guidelines in 1993, which came into force in 1994 [25]. At present there is no absolute requirement from any of the major regulatory authorities for the development of single enantiomer drugs and t ...
... statement for the development of new stereoisomeric drugs [24], which was closely followed by European guidelines in 1993, which came into force in 1994 [25]. At present there is no absolute requirement from any of the major regulatory authorities for the development of single enantiomer drugs and t ...
Treatment of Tuberculosis
... Use of monotherapy allows the selective growth of the resistant organisms and gives rise to drug resistance A prolonged course of antibiotics is required to kill the semi-dormant and dormant organisms ...
... Use of monotherapy allows the selective growth of the resistant organisms and gives rise to drug resistance A prolonged course of antibiotics is required to kill the semi-dormant and dormant organisms ...
Considerations When Tampering Occurs
... When diversion by tampering and substitution is suspected, there should be a defined process for assessing for the likelihood that patients have been harmed. The process should include a realistic discussion of the risks. Cases have been reported in which an ER nurse tampered with morphine or hydrom ...
... When diversion by tampering and substitution is suspected, there should be a defined process for assessing for the likelihood that patients have been harmed. The process should include a realistic discussion of the risks. Cases have been reported in which an ER nurse tampered with morphine or hydrom ...
Slide 1
... Rates and Dosing Regimen • Intrathecal, injectable cytarabine for lymphomatous meningitis – Severe complication of lymphoma ...
... Rates and Dosing Regimen • Intrathecal, injectable cytarabine for lymphomatous meningitis – Severe complication of lymphoma ...
Primary Care Update
... than 40% changed to drug 35% was or recommended less by an only for150self-identified tality and Morbidity in Heart Failure Trial), black patients who continued to have symptoms McMurray et al. report that LCZ696, as comto the protocol) and who were redespite evidence-based treatment.1 The aldoste- ...
... than 40% changed to drug 35% was or recommended less by an only for150self-identified tality and Morbidity in Heart Failure Trial), black patients who continued to have symptoms McMurray et al. report that LCZ696, as comto the protocol) and who were redespite evidence-based treatment.1 The aldoste- ...
Owner of MEXATE mark fails to prevent use of MEXT India
... With regard to the get-up and packaging of the goods, the court observed that Wallace sold its product in cardboard packaging, whereas Cadila sold its product in a foil pack. The court thus concluded that the overall get-up of the goods was dissimilar. The court also took into account the fact that ...
... With regard to the get-up and packaging of the goods, the court observed that Wallace sold its product in cardboard packaging, whereas Cadila sold its product in a foil pack. The court thus concluded that the overall get-up of the goods was dissimilar. The court also took into account the fact that ...
Strategic Analysis for Sanofi-Aventis Group Group Project
... 100,000 people across various locations. As the third largest pharmaceutical companies in the world, Sanofi-Aventis has solid resources and capabilities to support its healthy growth. Especially its world market presence in a few therapeutic areas with big potential growth, its strength in research ...
... 100,000 people across various locations. As the third largest pharmaceutical companies in the world, Sanofi-Aventis has solid resources and capabilities to support its healthy growth. Especially its world market presence in a few therapeutic areas with big potential growth, its strength in research ...
View - Sanofi
... Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic potential of MYK-461 and MYK-491, the Company's ability to advan ...
... Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic potential of MYK-461 and MYK-491, the Company's ability to advan ...
Practical Pharmacokinetics for the Bedside Clinician
... discharge counseling. What considerations might you take into account? A. MA is giving up smoking and therefore will be more sensitive to the effects of caffeine B. MA may be at risk of stent thrombosis secondary to suboptimal therapy from the antiplatelets she has been prescribed C. Both of the abo ...
... discharge counseling. What considerations might you take into account? A. MA is giving up smoking and therefore will be more sensitive to the effects of caffeine B. MA may be at risk of stent thrombosis secondary to suboptimal therapy from the antiplatelets she has been prescribed C. Both of the abo ...
STSE #1 Drugs and Homeostasis - Marystown Central High School
... mood. A danger of MAOI’s and tricyclic compounds is the increased risk of heart failure. MAO inhibitors can not be taken with certain foods such as cheese, avocado, and wine because this interaction will raise blood pressure that can cause heart failure and death. Usually, doctors will avoid prescri ...
... mood. A danger of MAOI’s and tricyclic compounds is the increased risk of heart failure. MAO inhibitors can not be taken with certain foods such as cheese, avocado, and wine because this interaction will raise blood pressure that can cause heart failure and death. Usually, doctors will avoid prescri ...
General Pharmakokinetics
... diazepam, amitriptyline). c) Activation of inactive drug. Few drugs (so called prodrugs) are inactive as such. They need conversion in the body to one or more active metabolites (e.g. levodopa, benfothiamine, enalapril, perindopril). The prodrug may offer advantages: their active forms may be more s ...
... diazepam, amitriptyline). c) Activation of inactive drug. Few drugs (so called prodrugs) are inactive as such. They need conversion in the body to one or more active metabolites (e.g. levodopa, benfothiamine, enalapril, perindopril). The prodrug may offer advantages: their active forms may be more s ...
From Natural Product to clinical trial
... 91% of patients with these two response predictors han at least a 0.5log10 viral load reduction by week 2 with a maximum treatment response of 2.03log10 ...
... 91% of patients with these two response predictors han at least a 0.5log10 viral load reduction by week 2 with a maximum treatment response of 2.03log10 ...
Chapter 1 - Drug Discovery and Development: An Overview of
... ones are not? Of the useful compounds, which ones will be of interest to the companies that manufacture drugs and which ones will not? These issues are exceptionally complex, and become even more so, when the health issue is something other than an invading organism. In considering chronic pain mana ...
... ones are not? Of the useful compounds, which ones will be of interest to the companies that manufacture drugs and which ones will not? These issues are exceptionally complex, and become even more so, when the health issue is something other than an invading organism. In considering chronic pain mana ...
FDA DOSSIER : LYNPARZA® Olaparib
... Histologically or, cytologically confirmed malignant solid tumor refractory to standard therapy and for which no suitable effective standard therapy exists For the ovarian cancer : progressive or recurrent disease according to RECIST 1.1 ...
... Histologically or, cytologically confirmed malignant solid tumor refractory to standard therapy and for which no suitable effective standard therapy exists For the ovarian cancer : progressive or recurrent disease according to RECIST 1.1 ...
Heart Failure:
... many of the co-morbidities facing our elderly residents, this disease is also often misdiagnosed and not optimally treated. Parkinson’s is defined by having two of four specific symptoms: resting tremor, muscular rigidity, gait instability and bradykinesia. Parkinson’s Disease is caused by a deficie ...
... many of the co-morbidities facing our elderly residents, this disease is also often misdiagnosed and not optimally treated. Parkinson’s is defined by having two of four specific symptoms: resting tremor, muscular rigidity, gait instability and bradykinesia. Parkinson’s Disease is caused by a deficie ...
Mechanism of DI
... leaves & flowers 450 mg bid (1 dose = 84.3 mg of oligomeric procyanides) led to decrease of maximal plasma concentration of digoxine by 14 % and minimal plasma ...
... leaves & flowers 450 mg bid (1 dose = 84.3 mg of oligomeric procyanides) led to decrease of maximal plasma concentration of digoxine by 14 % and minimal plasma ...
Performance Enhancing Drugs Creatine Risks
... Supplements are considered food and not drugs by the FDA. This means supplement manufacturers are not required to conform to the same standards as drug manufacturers do. In some cases, supplements have been found to be contaminated with other substances, which may inadvertently lead to a positive te ...
... Supplements are considered food and not drugs by the FDA. This means supplement manufacturers are not required to conform to the same standards as drug manufacturers do. In some cases, supplements have been found to be contaminated with other substances, which may inadvertently lead to a positive te ...
Neurobiology of Drug Addiction - National Center for State Courts
... Modified from: Heimer L and Alheid G, Piecing together the puzzle of basal forebrain anatomy. In: Napier TC, Kalivas PW and Hanin I (Eds), The Basal Forebrain: Anatomy to Function (series title: Advances in Experimental Medicine and Biology, Vol. 295), Plenum Press, New York, 1991, pp. 1-42. ...
... Modified from: Heimer L and Alheid G, Piecing together the puzzle of basal forebrain anatomy. In: Napier TC, Kalivas PW and Hanin I (Eds), The Basal Forebrain: Anatomy to Function (series title: Advances in Experimental Medicine and Biology, Vol. 295), Plenum Press, New York, 1991, pp. 1-42. ...
Nardil - Pfizer
... treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major depressive disorder (MDD) and oth ...
... treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major depressive disorder (MDD) and oth ...
File - Wk 1-2
... Quantitative Aspects of Drug-Receptor Interactions The binding reaction: Binding of drugs to receptors necessarily obeys the Law of Mass Action (the rate of chemical reaction is proportional to the product of concentrations of the reactants) Example from book: A piece of heart muscle contains a tot ...
... Quantitative Aspects of Drug-Receptor Interactions The binding reaction: Binding of drugs to receptors necessarily obeys the Law of Mass Action (the rate of chemical reaction is proportional to the product of concentrations of the reactants) Example from book: A piece of heart muscle contains a tot ...
Slide 1
... benchmarked against historical parameters — Absolute probability of approval as well as comparison to similar agents ...
... benchmarked against historical parameters — Absolute probability of approval as well as comparison to similar agents ...
Bioavailability
... determined when two products are compared to each other, not to an intravenous standard. This is commonly calculated in the generic drug industry to determine that the generic formulation (e.g., a tablet) is bioequivalent to the original formulation (e.g., another tablet). Thus, bioavailability is n ...
... determined when two products are compared to each other, not to an intravenous standard. This is commonly calculated in the generic drug industry to determine that the generic formulation (e.g., a tablet) is bioequivalent to the original formulation (e.g., another tablet). Thus, bioavailability is n ...
methamphetamine has a high potential for abuse
... systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics". It has not been established, however, that the action of such drugs in treating obesity is primarily one of appe ...
... systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics". It has not been established, however, that the action of such drugs in treating obesity is primarily one of appe ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.